Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35671005.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0932 and PMC identifier 9357158.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277.
Medical subject headings
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma